Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC.

ABSTRACT:

SUBMITTER: Ma L 

PROVIDER: S-EPMC11868279 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature